BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Alexion Appoints Francois Nader, M.D. to Its Board of Directors

  Dr. Nader is an accomplished leader in the biopharmaceutical industry with a proven track record of building and transforming companies, launching rare disease therapies, and creating significant shareholder value.

  November 8, 2017

   · 

  4 min read
• Genetown

  Akebia Therapeutics Announces Third Quarter 2017 Financial Results

  Akebia reported a net loss of ($23.1) million, or ($0.49) per share, for the third quarter of 2017 as compared to a net loss for the third quarter of 2016 of ($36.3) million or ($0.96) per share.

  November 8, 2017

   · 

  7 min read
• In Line With the Business Plan Presented at the IPO, ASIT Biotech Prepares an Additional Fund Raising to Further Develop its Products

  The new shares will be issued without a discount on the average share price of the last 30 days preceding the issue of the new shares.

  November 8, 2017

   · 

  12 min read
• Business

  Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram

  Ingram’s decision to resign as a director from the Company’s Board of Directors effective November 6, 2017 is due to his appointment as President and CEO of Sarepta Therapeutics earlier this year.

  November 8, 2017

   · 

  4 min read
• Biotech Beach

  Regen BioPharma’s Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs

  The company recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor.

  November 8, 2017

   · 

  3 min read
• FDA

  Orthocell Receives CE Mark for CelGro

  CelGro, for a range of dental bone and soft tissue regeneration procedures, can now be marketed and sold within the European Union (EU).

  November 8, 2017

   · 

  4 min read
• Business

  Editas Medicine Announces Third Quarter 2017 Results and Update

  Cash, cash equivalents, and marketable securities at September 30, 2017, were $295.7 million, compared to $199.9 million at September 30, 2016.

  November 8, 2017

   · 

  9 min read
• Business

  Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program

  The company reported a net loss of approximately $2.7 million, or $0.12 per share, for the third quarter of 2017, compared to a net loss of approximately $5.3 million, or $0.29 per share, for the third quarter of 2016.

  November 8, 2017

   · 

  14 min read
• Business

  Vermillion Reports Third Quarter 2017 Results

  Conference call is scheduled for 4:30 p.m. ET today.

  November 8, 2017

   · 

  18 min read
• Business

  Natera Reports Third Quarter 2017 Financial Results

  Generated total revenues of $56.7 million in the third quarter of 2017 compared to $53.9 million in the third quarter of 2016.

  November 8, 2017

   · 

  22 min read